The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Leptomeningeal disease: current diagnostic and therapeutic strategies
Open accessAbstract
// Gautam Nayar 1, 2, 3 , Tiffany Ejikeme 1, 2, 3 , Pakawat Chongsathidkiet 1, 2, 6 , Aladine A. Elsamadicy 1, 2, 3 , Kimberly L. Blackwell 4 , Jeffrey M. Clarke 5 , Shivanand P. Lad 3 and Peter E. Fecci 1, 2, 3, 6 1 Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA 2 The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA 3 Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA 4 Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA 5 Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA 6 Department of Pathology, Duke University Medical Center, Durham, NC, USA Correspondence to: Peter E. Fecci, email: Peter.fecci@duke.edu Keywords: leptomeningeal disease, neoplastic meningitis, leptomeningeal carcinomatosis, intrathecal chemotherapy, radiation therapy Received: May 10, 2017 Accepted: July 20, 2017 Published: August 16, 2017 ABSTRACT Leptomeningeal disease has become increasingly prevalent as novel therapeutic interventions extend the survival of cancer patients. Although a majority of leptomeningeal spread occurs secondary to breast cancer, lung cancer, and melanoma, a wide variety of malignancies have been reported as primary sources. Symptoms on presentation are equally diverse, often involving a combination of neurological deficits with the possibility of obstructive hydrocephalus. Diagnosis is definitively made via cerebrospinal fluid cytology for malignant cells, but neuro-imaging with high quality T1-weighted magnetic resonance imaging can aid diagnosis and localization. While leptomeningeal disease is still a terminal, late-stage complication, a variety of treatment modalities, such as intrathecal chemotherapeutics and radiation therapy, have improved median survival from 4–6 weeks to 3–6 months. Positive prognosticative factors for survival include younger age, high performance scores, and controlled systemic disease. In looking to the future, diagnostics that improve early detection and chemotherapeutics tailored to the primary malignancy will likely be the most significant advances in improving survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Cited by
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“LMD is a deadly complication of solid tumours and is associated with a poor prognosis.”
BackgroundInfluentialWu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
Leptomeningeal carcinomatosis in patients with breast cancer
Franzoi, M. A., & Hortobagyi, G. N. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.020 · Cited by 149
Metadata
- Authors
- Nayar, G., Ejikeme, T., Chongsathidkiet, P., Elsamadicy, A. A., Blackwell, K. L., Clarke, J. M., Lad, S. P., & Fecci, P. E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-08-16
- Volume
- 8
- Issue
- 42
- Pages
- 73312-73328
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2746646750
- Cited by
- 234
- References
- 5
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leptomeningeal disease: current diagnostic and therapeutic strategies. https://app.cochat.ai/papers/10.18632/oncotarget.20272
- The paper
- Nayar, G., Ejikeme, T., Chongsathidkiet, P., Elsamadicy, A. A., Blackwell, K. L., Clarke, J. M., Lad, S. P., & Fecci, P. E. (2017). Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. https://doi.org/10.18632/oncotarget.20272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.